Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

323 ARTÍCULOS , VIENDO DEL 181 AL 195

Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality

Vilalta-Franch J, López-Pousa S, Calvó-Perxas L, Garre-Olmo J.

Am J Geriatr Psychiatry. 2013 Nov;21(11):1135-43. doi: 10.1016/j.jagp.2013.01.051. Epub 2013 Feb 6.

Caregivers of Alzheimer's patients and factors influencing institutionalization of loved ones: some considerations on existing literature

Sansoni J, Anderson KH, Varona LM, Varela G.

Ann Ig. 2013 May-Jun;25(3):235-46. doi: 10.7416/ai.2013.1926.

Progranulin mutations as risk factors for Alzheimer disease

Perry DC, Lehmann M, Yokoyama JS, Karydas A, Lee JJ, Coppola G, Grinberg LT, Geschwind D, Seeley WW, Miller BL, Rosen H, Rabinovici G.

JAMA Neurol. 2013 Jun;70(6):774-8. doi: 10.1001/2013.jamaneurol.393.

Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies

Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd.

Br J Psychiatry. 2013 May;202(5):329-35. doi: 10.1192/bjp.bp.112.118307.

Alzheimer's disease, dementia, mild cognitive impairment and the menopause: a 'window of opportunity'?

Davey DA.

Womens Health (Lond). 2013 May;9(3):279-90. doi: 10.2217/whe.13.22.

Amyloid imaging with PET in early Alzheimer disease diagnosis

Rowe CC, Villemagne VL.

Med Clin North Am. 2013 May;97(3):377-98. doi: 10.1016/j.mcna.2012.12.017.

Emotional and psychological implications of early AD diagnosis

Antoine P, Pasquier F.

Med Clin North Am. 2013 May;97(3):459-75. doi: 10.1016/j.mcna.2012.12.015. Epub 2013 Feb 6.

Does a positive Pittsburgh Compound B scan in a patient with dementia equal Alzheimer disease?

Ducharme S, Guiot MC, Nikelski J, Chertkow H.

JAMA Neurol. 2013 Jul;70(7):912-4. doi: 10.1001/jamaneurol.2013.420.

Novel white matter tract integrity metrics sensitive to Alzheimer disease progression

Fieremans E, Benitez A, Jensen JH, Falangola MF, Tabesh A, Deardorff RL, Spampinato MV, Babb JS, Novikov DS, Ferris SH, Helpern JA.

AJNR Am J Neuroradiol. 2013 Nov-Dec;34(11):2105-12. doi: 10.3174/ajnr.A3553. Epub 2013 Jun 13.

Medication adherence and tolerability of Alzheimer's disease medications: study protocol for a randomized controlled trial

Campbell NL, Dexter P, Perkins AJ, Gao S, Li L, Skaar TC, Frame A, Hendrie HC, Callahan CM, Boustani MA.

Trials. 2013 May 4;14:125. doi: 10.1186/1745-6215-14-125.

Perceptual and response interference in Alzheimer's disease and mild cognitive impairment

Wang P, Zhang X, Liu Y, Liu S, Zhou B, Zhang Z, Yao H, Zhang X, Jiang T.

Clin Neurophysiol. 2013 Dec;124(12):2389-96. doi: 10.1016/j.clinph.2013.05.014. Epub 2013 Jun 17.

[Relationship between memory disorders and self-consciousness in Alzheimer's disease]

Kalenzaga S, Clarys D.

Geriatr Psychol Neuropsychiatr Vieil. 2013 Jun;11(2):187-96. doi: 10.1684/pnv.2013.0403.

Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging

Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Hedrick S, Pappas V, Carrillo MC, Hartley DM; Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging.

Alzheimers Dement. 2013 Jul;9(4):e106-9. doi: 10.1016/j.jalz.2013.06.001.

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Utility in detection and characterization of mild cognitive impairment due to Alzheimer's disease

Karantzoulis S, Novitski J, Gold M, Randolph C.

Arch Clin Neuropsychol. 2013 Dec;28(8):837-44. doi: 10.1093/arclin/act057. Epub 2013 Jul 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias